Flow diverter treatment of intracranial vertebral artery dissecting pseudoaneurysms
- PMID: 28438894
- DOI: 10.1136/neurintsurg-2017-013020
Flow diverter treatment of intracranial vertebral artery dissecting pseudoaneurysms
Abstract
Introduction: Intracranial vertebral dissecting pseudoaneurysms are a rare, but increasingly recognized, cause of subarachnoid hemorrhage and ischemic stroke. The risks of aneurysm re-rupture and associated morbidity are high. The use of flow diverter stents for the treatment of these aneurysms has not been well studied.
Objective: To report our data and provide a summarized review of literature using flow diverter stents for the treatment of intracranial vertebral artery dissecting pseudoaneurysms.
Methods: We performed a retrospective analysis of flow diverter stents used for the treatment of intracranial vertebral artery dissecting pseudoaneurysms. Clinical, imaging, procedural, and follow-up data were collected.
Results: We identified eight vertebral dissecting pseudoaneurysms in seven patients (5 (71.4%) female; median age 47 years (IQR 46-52)) who had undergone treatment with flow diverter stents. In 4/7 patients (57.1%) the aneurysm had ruptured; however, only one was treated in the acute phase. Median size of the largest diameter of the aneurysm was 6.3 mm (IQR 4.2-8.8), and 7/8 aneurysms (87.5%) were treated with a single flow diverter device. Three aneurysms were concurrently coiled. Angiographic complete occlusion was seen in 6/8 (75%) aneurysms at a median follow-up of 14 months (IQR 7.7-20.2). Two patients had periprocedural strokes with transient neurologic deficits. All patients had a good clinical outcome (modified Rankin Scale score ≤2). There were no re-treatments or aneurysm ruptures during the follow-up period.
Conclusions: Our experience suggests that flow diverter stent treatment of intracranial vertebral artery dissecting pseudoaneurysms is safe, and associated with good occlusion rates and favorable clinical outcomes.
Keywords: Aneurysm; Dissection; Flow Diverter.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
Competing interests: MB: Codman and Stryker consultant. Clinical Events Committee for the BARREL trial. MSH: Pulsar Inc, Clinical Events Committee. PR: Medtronic Neurovascular—Scientific Advisory Board; Genentech—consultant/honorarium; Nervive Medical—Scientific Advisory Board and stock holder; Perflow Medical—Scientific Advisory Board and stock holder; Stryker Neurovascular—Scientific Advisory Board. GT: Data Safety Monitoring Board for the COMPASS trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical